Skip to main content

Table 1 Characteristics of medication dataset at baseline. Only the time up to the first SRC is considered

From: ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis

 Patients with SRC (N = 102)Patients without SRC (N = 7546)Median # or risk difference (95% CI)P value
Median (IQR) or no. of patients (%)
Age (years)57.3 (48.0 to 67.9)56.4 (46.0 to 65.7)1.3 (− 1.3 to 3.9)0.36
Sex (female)80/102 (78%)6484/7546 (86%)− 7% (− 16 to 1%)0.031
Time between onset of scleroderma and inclusion (y)*5.0 (1.9 to 10.9)7.0 (3.1 to 13.2)− 1.3 (− 2.5 to − 0.3)0.019
Extent of skin involvement0.005
 No skin involvement4/100 (4%)306/7312 (4%)  
 Only sclerodactyly11/100 (11%)785/7312 (11%)  
 Limited cutaneous involvement41/100 (41%)4151/7312 (57%)  
 Diffuse cutaneous involvement44/100 (44%)2070/7312 (28%)  
Glucocorticoids37/90 (41%)2437/6644 (37%)4% (− 6 to 15%)0.39
Dose at baseline (if > 0), mg7.5 (5.0 to 10.0)5.0 (5.0 to 10.0)0.0 (0.0 to 2.0)0.16
Glucocorticoids > 10 mg5/90 (6%)295/6644 (4%)1% (− 4 to 6%)0.61
Glucocorticoids > 15 mg3/90 (3%)171/6644 (3%)1% (− 3 to 4%)0.65
ACE inhibitors34/96 (35%)1299/7163 (18%)17% (8 to 27%)< 0.001
Angiotensin receptor blocker6/96 (6%)654/7150 (9%)− 3% (− 8 to 2%)0.33
Calcium channel blockers50/96 (52%)3763/7178 (52%)− 0% (− 10 to 10%)0.95
Endothelin receptor antagonist12/85 (14%)727/6165 (12%)2% (− 5 to 10%)0.51
PDE5 inhibitors6/91 (7%)321/6649 (5%)2% (− 3 to 7%)0.44
  1. *Missing data for 10 patients with and 982 patients without SRC
  2. #Generalized Hodges-Lehmann median differences